文献速递医学人工智能与信息学临床试验与 GCP

基于人工智能的病理工具用于代谢功能障碍相关脂肪性肝炎评分的临床验证

Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis.
PubMed 文献 · Nat Med · 2024-11-04

本研究对人工智能病理系统AIM-MASH进行了多中心分析与临床验证,用于辅助病理医生在MASH临床试验中进行组织学评分。AIM-MASH的重复性和再现性高于人工评分,专家病理医生在AIM-MASH辅助下对炎症、气球样变、MAS≥4且各评分类别均≥1分及MASH缓解的评估准确度优于无辅助阅读,同时在脂肪变和纤维化评估上保持非劣效。

要点

  • AIM-MASH的重复性和再现性高于人工评分。
  • AIM-MASH辅助阅读在炎症、气球样变、MAS≥4且各评分类别均≥1分及MASH缓解评估上优于无辅助阅读。
  • AIM-MASH辅助阅读在脂肪变和纤维化评估上保持非劣效。

核心结论

  • AIM-MASH可减轻阅片者变异性,为MASH临床试验中的治疗评估提供更可靠的评价。

研究设计与样本

  • 本研究为对基于人工智能的病理系统AIM-MASH开展的多中心分析与临床验证研究。

主要发现

  • AIM-MASH的重复性和再现性高于人工评分。
  • 专家MASH病理医生在AIM-MASH辅助下对炎症、气球样变、MAS≥4且各评分类别均≥1分及MASH缓解的评估准确度优于无辅助阅读。
  • AIM-MASH辅助阅读在脂肪变和纤维化评估上保持非劣效。

临床怎么用

  • 作者认为AIM-MASH可减轻阅片者变异性,为MASH临床试验中的治疗评估提供更可靠的评价。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatohepatitis (MASH) is a major cause of liver-related morbidity and mortality, yet treatment options are limited. Manual scoring of liver biopsies, currently the gold standard for clinical trial enrollment and endpoint assessment, suffers from high reader variability. This study represents the most comprehensive multisite analytical and clinical validation of an artificial intelligence (AI)-based pathology system, AI-based measurement of metabolic dysfunction-associated steatohepatitis (AIM-MASH), to assist pathologists in MASH trial histology scoring. AIM-MASH demonstrated high repeatability and reproducibility compared to manual scoring. AIM-MASH-assisted reads by expert MASH pathologists were superior to unassisted reads in accurately assessing inflammation, ballooning, MAS ≥ 4 with ≥1 in each score category and MASH resolution, while maintaining non-inferiority in steatosis and fibrosis assessment. These findings suggest that AIM-MASH could mitigate reader variability, providing a more reliable assessment of therapeutics in MASH clinical trials.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Pulaski H, Harrison SA, Mehta SS, et al. Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis. Nat Med. 2024. PMID: 39496972. doi:10.1038/s41591-024-03301-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。